Vobarilizumab (anti-IL-6Ra), 白细胞介素-6 受体抗体

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175700-100μg	100μg	现货
Ab175700-1mg	1mg	现货
Ab175700-5mg	5mg	现货
Ab175700-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: IL6R 点击查看靶蛋白信息: IL6ST

Accession#:P08887 (9) Gene ID:3570 (9) IL6R (10) Interleukin-6 receptor Antibody (2)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Vobarilizumab (anti-IL-6Ra), 白细胞介素-6 受体抗体
别名	沃巴利珠单抗 \| 沃巴利珠单抗（抗 IL-6Ra）
英文别名	CD 126 antibody \| CD126 antibody \| CD126 antigen antibody \| gp80 antibody \| IL 6R 1 antibody \| IL 6R alpha antibody \| IL 6R antibody \| IL-6 receptor alpha chain antibody \| IL-6 receptor subunit alpha antibody \| IL-6R 1 antibody \| IL-6R subunit alpha antib
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	IL6R
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	白细胞介素-6 受体抗体

产品属性

克隆类型	重组抗体
Format	scFv
亚型	Human IgG1
SDS-PAGE	78.2 kDa
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1628814-88-9
分子类型	抗体

关联靶点（人）

IL6R Tclin 白细胞介素-6 受体亚基 α(Interleukin-6 receptor subunit alpha) (0 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

IL6ST Tclin 白细胞介素-6受体亚基β(Interleukin-6 receptor subunit beta) (0 活性数据)

点击查看靶蛋白信息： IL6ST

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

IL6R Tclin Interleukin-6 receptor alpha subunit (0 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

IL6ST Tclin Interleukin-6 receptor subunit beta (58 活性数据)

点击查看靶蛋白信息： IL6ST

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

IL6R Tclin IL6Ralpha/GP130 (4 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

ELISA: Vobarilizumab (anti-IL-6Ra) (Ab175700)

Vobarilizumab (anti-IL-6Ra) (Ab175700) - ELISA
Immobilized human IL-6R-ECD-chis at 2.0 μg/mL can Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC₅₀ of 13.89 ng/mL.

SEC: Vobarilizumab (anti-IL-6Ra) (Ab175700)

Vobarilizumab (anti-IL-6Ra) (Ab175700) - SEC
The purity of Vobarilizumab (anti-IL-6Ra) (Ab175700) is more than 95% verified by HPLC.

ELISA: Vobarilizumab (anti-IL-6Ra) (Ab175700)

Vobarilizumab (anti-IL-6Ra) (Ab175700) - ELISA
Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC50 of 67.99 ng/mL.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ24F1114505	分析证书	Ab175700
ZJ24F1114504	分析证书	Ab175700
ZJ24F1114503	分析证书	Ab175700

可替换产品

引用文献

1. Tackey E, Lipsky PE, Illei GG. (2004) Rationale for interleukin-6 blockade in systemic lupus erythematosus.. Lupus, 13 (5): (339-43). [PMID:15230289]
2. Kristiansen OP, Mandrup-Poulsen T. (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes, 54 Suppl 2 (S114-24). [PMID:16306329]
3. Hirohata S, Kikuchi H. (2012) Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease.. Intern Med, 51 (24): (3359-65). [PMID:23257520]
4. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (135). [PMID:25994180]
5. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033]
6. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182]
7. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785]
8. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] [10.1016/j.immuni.2019.03.026]
9. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C.. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.. J Med Chem, 57 (3): (632-641). [PMID:24456369] [10.1021/jm401144z]
10. Schooltink, H H and 7 more authors.. (1991) Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells.. The Biochemical journal, (1): [PMID:1872801]
11. Novick, D D, Engelmann, H H, Wallach, D D and Rubinstein, M M.. (1989) Soluble cytokine receptors are present in normal human urine.. The Journal of experimental medicine, (1): [PMID:2529343]
12. Yamasaki, K K and 8 more authors.. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.. Science (New York, N.Y.), (12): [PMID:3136546]
13. Horiuchi, S S and 8 more authors.. (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.. European journal of immunology, [PMID:8056053]
14. Yawata, H H and 7 more authors.. (1993) Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130.. The EMBO journal, [PMID:8467812]
15. Cole, A R AR and 6 more authors.. (1999) Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.. The Journal of biological chemistry, (12): [PMID:10066782]
16. Martens, A S AS, Bode, J G JG, Heinrich, P C PC and Graeve, L L.. (2000) The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized madin-darby canine kidney cells.. Journal of cell science, [PMID:11017875]
17. Nakahara, Hideko H and 6 more authors.. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.. Arthritis and rheumatism, [PMID:12794819]
18. Buk, Deborah M DM, Renner, Olga O and Graeve, Lutz L.. (2005) Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80.. European journal of cell biology, [PMID:16270750]
19. Smolen, Josef S JS and Maini, Ravinder N RN.. (2006) Interleukin-6: a new therapeutic target.. Arthritis research & therapy, [PMID:16899109]
20. Reich, David D and 23 more authors.. (2007) Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.. American journal of human genetics, [PMID:17357077]
21. Betts, Brian C BC, St Angelo, Erin T ET, Kennedy, Michael M and Young, James W JW.. (2011) Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.. Blood, (10): [PMID:21940820]
22. Huizinga, Tom W J TW and 9 more authors.. (2014) Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.. Annals of the rheumatic diseases, [PMID:24297381]
23. and Lin, Phoebe P.. (2015) Targeting interleukin-6 for noninfectious uveitis.. Clinical ophthalmology (Auckland, N.Z.), [PMID:26392750]
24. Lokau, Juliane J and 13 more authors.. (2016) Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.. Cell reports, (23): [PMID:26876177]
25. June, Rayford R RR and Olsen, Nancy J NJ.. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.. Expert opinion on biological therapy, [PMID:27464017]
26. Riethmueller, Steffen S and 23 more authors.. (2017) Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.. PLoS biology, [PMID:28060820]
27. Smolen, Josef S JS and 48 more authors.. (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.. Annals of the rheumatic diseases, [PMID:28264816]
28. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003]
29. Kampan, Nirmala Chandralega NC and 5 more authors.. (2018) Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.. Current medicinal chemistry, [PMID:28707587]
30. Spencer, Sarah and 37 more authors.. (2019) Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.. The Journal of experimental medicine, (2): [PMID:31235509]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Vobarilizumab (anti-IL-6Ra), 白细胞介素-6 受体抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器